4 completed, 3 active not recruiting, 1 recruiting. 3 Not applicable, 1 Early Phase 1, 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8: new trials by email Literature Review of Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8 trials Research Report on Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events Best Practice, Patient Monitoring, Questionnaire Administration - Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8 | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 750 | 2021-05-12 | 2026-06-16 |
| Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers Adavosertib, Radiation Therapy - Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 4 | 2021-04-09 | 2026-07-31 |
| Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes Patient Monitoring, Questionnaire Administration - Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 | Completed | City of Hope Medical Center | 22 | 2020-08-11 | 2026-10-14 | |
| Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers Radiation Therapy (RT) - Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma | Not applicable | Recruiting | University of California, San Francisco | 28 | 2020-08-07 | 2026-08-14 |
| Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body Capecitabine, Fluorouracil, Leucovorin - Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8 | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 314 | 2020-05-26 | 2026-10-19 |
| Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study Patient Monitoring System, Questionnaire Administration, Consultation - Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 | Not applicable | Completed | Thomas Jefferson University | 34 | 2020-04-15 | 2025-05-15 |
| Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma Trifluridine and Tipiracil Hydrochloride, Oxaliplatin - Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Completed | Roswell Park Cancer Institute | 22 | 2019-12-20 | 2025-04-29 |
| Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma Pembrolizumab - Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 9 | 2018-02-09 | 2023-11-18 |
Adenocarcinoma Of Esophagus (3) · Colorectal Neoplasms (3) · Gastrointestinal Neoplasms (3) · Carcinoma, Hepatocellular (2) · Esophageal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Pancreatic Neoplasms (2) · Stomach Neoplasms (2) · Anal Canal Carcinoma (1) · Anus Neoplasms (1) · Brain Neoplasms (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Meningeal Carcinomatosis (1) · Neoplasms (1)
Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gastrointestinal Diseases (5) · Neoplasms by Site (5) · Carcinoma (4) · Colonic Diseases (4) · Intestinal Diseases (4) · Intestinal Neoplasms (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Rectal Diseases (4) · Adenocarcinoma (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3)
Radiation (3) · Radiotherapy (3) · Oxaliplatin (2) · Remote Patient Monitoring (2) · Capecitabine (1) · Fluorouracil (1) · Leucovorin (1) · Practice Guidelines as Topic (1) · Referral and Consultation (1) · Standard of Care (1) · Thymidine (1) · Trifluridine (1) · adavosertib (1) · dehydroftorafur (1) · pembrolizumab (1)
M.D. Anderson Cancer Center (2) · City of Hope Medical Center (1) · ECOG-ACRIN Cancer Research Group (1) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1) · Thomas Jefferson University (1) · University of California, San Francisco (1)
United States (8)
Christos Fountilas, MD (1) · Eric D Miller (1) · Jaffer A Ajani (1) · Kuang-Yi Wen, MD (1) · Laleh Melstrom (1) · Mary Feng, MD (1) · Nataliya V Uboha (1) · Ryan W Huey, MD (1)
PMID 35602670, PMID 36821818, PMID 40200573
P30CA033572 (1), U10CA180820 (1), UM1CA186712 (1)